A recent study has provided compelling evidence supporting the de-escalation of broad-spectrum antibiotics in certain patients suffering from community-onset sepsis. This research indicates that it is not only safe but also clinically appropriate to reduce the use of these powerful antibiotics when there are no signs of a multidrug-resistant organism (MDRO).
Conducted across 67 hospitals in Michigan and involving nearly 37,000 patients, this investigation reveals that sepsis patients who were transitioned away from antibiotics designed to target methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (PSA) by the fourth day of treatment experienced similar rates of 90-day all-cause mortality when compared to those who continued on the broader regimen. Moreover, this de-escalation approach was linked to a reduction in the duration of antibiotic therapy and shorter hospital stays.
However, it's noteworthy that the rate at which patients were de-escalated varied significantly among the hospitals involved in the study, despite existing guidelines recommending this practice when MDROs are not present.
The findings of this research were published recently in JAMA Internal Medicine and reinforce the current sepsis management guidelines that advocate for antibiotic de-escalation where appropriate.
The Uncertainty Surrounding Clinical Practices
Led by experts from the Veterans Affairs Ann Arbor Healthcare System and the University of Michigan, the study analyzed patient data collected between June 2020 and September 2024 as part of the Michigan Hospital Medicine Safety Consortium, a statewide initiative aimed at enhancing the care of hospitalized patients who may be vulnerable to adverse events. The objective was to evaluate the outcomes associated with de-escalating broad-spectrum antibiotics versus continuing their use.
The 2021 Surviving Sepsis Campaign Guidelines recommend initiating early empiric broad-spectrum antibiotics, which have shown to lower mortality rates in sepsis patients at risk for MDRO infections. However, research indicates that only about 10% of sepsis patients actually harbor MDRO infections. Additionally, the use of broad-spectrum antibiotics can lead to serious complications, such as Clostridioides difficile infections, and contribute to the growing issue of antibiotic resistance. Therefore, shifting to narrower-spectrum antibiotics is advised when no MDROs are detected.
Despite these recommendations, the authors of the study express concern regarding the inconsistency of adherence to these practices in real-world clinical settings. Previous studies comparing the outcomes of de-escalation versus continued broad-spectrum antibiotic therapy have yielded mixed results; while some suggest benefits such as improved clinical outcomes and increased survival rates, others report no significant differences in mortality and potential adverse effects, including a rise in secondary infections.
"Consequently, the implications of antibiotic de-escalation in sepsis patients are still not fully understood," they stated.
Methodology and Findings
Employing a target trial emulation framework, which leverages observational data to replicate a randomized controlled trial design, the researchers conducted two separate studies. One examined sepsis patients without indicators of MDRO infection who were de-escalated from anti-MRSA therapy on day four, comparing them with those who continued receiving anti-MRSA treatments. The second study focused on patients de-escalated from anti-PSA therapy under the same conditions.
The primary outcome measured was the 90-day all-cause mortality rate, while secondary outcomes included in-hospital mortality, 30-day mortality rates, length of hospital stays, and total days of antibiotic therapy.
Interestingly, out of 36,924 patients (with a median age of 71, and 50.3% female) who were hospitalized with community-onset sepsis during this period, 6,926 (18.8%) and 11,149 (30.2%) qualified for the respective studies evaluating the de-escalation of anti-MRSA and anti-PSA antibiotics. Among these, 2,993 (43.2%) and 2,493 (22.4%) patients were successfully de-escalated from anti-MRSA and anti-PSA coverage by day four.
After adjusting for balance between the groups of patients who were de-escalated and those who continued treatment, the results indicated that both anti-MRSA and anti-PSA de-escalation were linked to mortality rates at 90 days comparable to those remaining on broad-spectrum antibiotics (anti-MRSA odds ratio [OR] of 1.00; anti-PSA OR of 0.98). Furthermore, those who underwent de-escalation required fewer days of antibiotic treatment up to day 14 (anti-MRSA risk ratio [RR] of 0.91; anti-PSA RR of 0.91) and had shorter hospital stays (anti-MRSA RR of 0.88; anti-PSA RR of 0.91). All other secondary outcomes showed similar trends.
"Overall, our findings provide further evidence that supporting antibiotic de-escalation is both safe and appropriate for patients hospitalized with community-onset sepsis, reinforcing guideline recommendations for its implementation in clinical practice," the authors concluded.
A Call for Consistency
Across the 67 hospitals studied, the percentage of eligible patients who were de-escalated from broad-spectrum antibiotics exhibited considerable variation, with anti-MRSA de-escalation rates ranging from 27.3% to 61.7%, and anti-PSA de-escalation rates from 6.9% to 37.7%. The authors speculate that the higher de-escalation rate for anti-MRSA antibiotics might reflect greater clinical confidence and the relative ease of transitioning away from these therapies.
In conclusion, the authors emphasize the need for prospective randomized studies to gain a clearer understanding of the impacts associated with de-escalating specific classes of antibiotics. These findings raise important questions about current practices: Are healthcare professionals consistently applying these guidelines in their treatment approaches? What barriers might exist that prevent the widespread adoption of antibiotic de-escalation strategies?
Engage with us in the comments—do you agree with the study's conclusions, or do you think there are critical factors that might challenge these findings?
